Evidence map›Paper›PMID 34191985›Full record

ArticleStatistics in biopharmaceutical research2020

Rejoinder to Letter to the Editor "The Hazards of Period Specific and Weighted Hazard Ratios".

Ray S Lin, Ji Lin, Satrajit Roychoudhury, Keaven M Anderson, Tianle Hu, Bo Huang, Larry F Leon, Jason J Z Liao, Rong Liu, Xiaodong Luo and 9 more

Abstract readLetter
In one paragraph

Article in Statistics in biopharmaceutical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ray S LinGenentech/Roche, South San Francisco, CA.
Ji LinSanofi US, Cambridge, MA.ORCID https://orcid.org/0000-0001-7206-6111
Satrajit RoychoudhuryPfizer Inc., New York, NY.ORCID https://orcid.org/0000-0003-4001-3036
Keaven M AndersonMerck & Co., Inc., North Wales, PA.
Tianle HuSarepta Therapeutics, Cambridge, MA.
Bo HuangPfizer Inc., Groton, CT.ORCID https://orcid.org/0000-0002-3088-9328
Larry F LeonCelgene Co., San Diego, CA.
Jason J Z LiaoMerck & Co., Inc., North Wales, PA.
Rong LiuCelgene Co., Summit, NJ.
Xiaodong LuoSanofi US, Bridgewater, NJ.
Pralay MukhopadhyayAstra Zeneca, Washington, DC.
Rui QinJanssen Research & Development, LLC, Raritan, NJ.
Kay TatsuokaBristol-Myers Squibb, Lawrenceville, NJ.
Xuejing WangEli Lilly and Company, Indianapolis, IN.
Yang WangTeclison Ltd., Montclair, NJ.
Jian ZhuServier Pharmaceuticals, Boston, MA.
Tai-Tsang ChenGSK, Collegeville, PA.
Renee IaconaAstra Zeneca, Washington, DC.
Cross-Pharma Non-Proportional Hazards Working Group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID34191985
PMCPMC8011488

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.